Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0707697Aexternal-prioritypatent/GB0707697D0/en
Priority claimed from GB0711357Aexternal-prioritypatent/GB0711357D0/en
Priority claimed from GB0712062Aexternal-prioritypatent/GB0712062D0/en
Priority claimed from GB0724651Aexternal-prioritypatent/GB0724651D0/en
Application filed by Glaxo Smithkline Biolog AfiledCriticalGlaxo Smithkline Biolog A
Publication of UY31024A1publicationCriticalpatent/UY31024A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
La presente invencion proporciona una composicion inmunogénica contra la gripe en un volumen de dosis adecuado para su uso en seres humanos, que comprende un antígeno del virus influenza o preparacion antigénica del mismo y una composicion de adyuvante que comprende una emulsion de aceite de agua, en la que dicha emulsion de aceite en agua comprende un aceite metabolizable a un nivel inferor a 11 mg y un agente emulsivo a un nivel inferior a 5 mg y opcionalmente un tocol o un esterol a un nivel inferior a 12 mg. Adecuadamente la cantidad de antígeno de la gripe por cepa por dosis es de 15 ug de HA o una cantidad baja tal como menos de 15 ug de HA.The present invention provides an immunogenic composition against influenza in a dose volume suitable for use in humans, comprising an influenza virus antigen or antigenic preparation thereof and an adjuvant composition comprising a water oil emulsion, in which said oil-in-water emulsion comprises a metabolizable oil at a level less than 11 mg and an emulsifying agent at a level below 5 mg and optionally a tocol or a sterol at a level below 12 mg. Suitably the amount of influenza antigen per strain per dose is 15 ug of HA or a low amount such as less than 15 ug of HA.
monovalent influenza vaccine composition, kit, method for producing an influenza vaccine composition for a pandemic or prepandemic situation, and uses of an influenza virus antigen or antigen preparation thereof and an adjuvant in an oil-in-water emulsion, a pandemic influenza virus antigen or antigen preparation of the influenza virus hemagglutinin antigen, a pandemic influenza virus or antigenic preparation thereof, and an oil-in-emulsion adjuvant water and an antigen or antigen preparation of a first strain of influenza
method of stabilizing cationic liposomes in aqueous formulations, liposome product, vaccine adjuvant, chlamydia, malaria or tuberculosis vaccine and delivery system